Centrient Pharmaceuticals
Centrient Pharmaceuticals, headquartered in the Netherlands, is a leading player in the global pharmaceutical industry, specialising in the development and manufacturing of essential antibiotics and anti-infectives. Founded in 2017, the company has quickly established itself as a key provider of high-quality, sustainable pharmaceutical solutions, with a strong operational presence across Europe, Asia, and North America. Centrient's core offerings include a diverse range of generic and branded antibiotics, as well as innovative formulations that address critical healthcare needs. The company is recognised for its commitment to sustainability and responsible manufacturing practices, setting it apart in a competitive market. With a focus on quality and patient safety, Centrient Pharmaceuticals continues to achieve significant milestones, reinforcing its position as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Centrient Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Centrient Pharmaceuticals's score of 32 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Centrient Pharmaceuticals's reported carbon emissions
In 2023, Centrient Pharmaceuticals reported total carbon emissions of approximately 448,232,000 kg CO2e. This figure includes 142,740,000 kg CO2e from Scope 1 emissions, 141,369,000 kg CO2e from Scope 2 emissions, and significant contributions from Scope 3 emissions, particularly 322,209,000 kg CO2e from purchased goods and services. Centrient has set ambitious climate commitments, aiming for a 35% reduction in carbon emission intensity by 2025 and a 50% reduction by 2030. Additionally, the company has committed to reducing absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by 2031, using 2022 as the base year. For Scope 3 emissions, specifically from purchased goods and services and fuel and energy-related activities, a target of 27.5% reduction is also set for the same timeframe. These targets align with industry standards and reflect Centrient's commitment to addressing climate change and reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 233,734,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Centrient Pharmaceuticals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
